PHA Australia

Pulmonary Arterial Hypertension and Cardiovascular Mortality in Patients With Rheumatoid Arthritis

This is a medscape article - please register with medscape it is free and we have lots of info come through this site. If not go to the message board under Pulmonary Hypertension and i can give you my log in details and just hit remember log in for your computer.

Phase II Results for Low-Dose Oral Immune Tolerance Therapy (ARG201) in Systemic Scleroderma Published

MEMPHIS, Tenn.--(BUSINESS WIRE)--arGentis Pharmaceuticals, LLC announced today that the Phase II results using highly purified type 1 bovine collagen orally (now known as ARG201) in the treatment of diffuse cutaneous systemic sclerosis (scleroderma – SSc) have been published in the June issue of Arthritis & Rheumatism, a major peer-reviewed rheumatology research journal.

Ikaria's INOflo (Nitric Oxide) for Inhalation Approved in Japan

karia to Market and Distribute INOflo via Partnership with Air Water Incorporated and Sumitomo Seika Chemicals

CLINTON, N.J., July 21, 2008 /PRNewswire/ -- Ikaria Holdings, Inc., through its subsidiary INO Therapeutics LLC, announced today that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved INOflo(R) (nitric oxide) for inhalation for improvement of hypoxic respiratory failure (HRF) with concurrent pulmonary hypertension in neonates.

Doctors Hope Better Blood Thinners Are On The Horizon

Doctors are hopeful three new experimental drugs will make treatment more accessible for millions of people at risk of lethal blood clots.

Two million patients currently use Coumadin, also known as warfarin, that causes an array of side effects and restrictions. The goal of the new drugs is to provide an alternative.

The first target is a pill option for people who now require daily blood-thinning shots for weeks after knee or hip replacement surgery.